Seeking Alpha

More on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena...

More on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena expects $66.5M in milestone payments from marketing and distribution partner Eisai in 2013, $6M from amortization of upfront payments, and $3M from manufacturing services from Siegfried. Arena also expects R&D costs of $70-78M and G&A expenses of $28-34M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|